Sustained delivery formulations of risperidone compounds

Details for Australian Patent Application No. 2008262545 (hide)

Owner QLT USA, Inc.

Inventors Dadey, Eric

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2008262545

PCT Pub. Number WO2008/153611

Priority 60/940,340 25.05.07 US

Filing date 13 February 2008

Wipo publication date 18 December 2008

International Classifications

A61K 47/34 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

Event Publications

14 January 2010 PCT application entered the National Phase

  PCT publication WO2008/153611 Priority application(s): WO2008/153611

11 February 2010 Amendment Made

  The nature of the amendment is: Amend the applicant name from QLT USA, Inc. to Tolmar Therapeutics, Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008262566-Compositions and methods for treating obesity and related disorders

2008262544-Use of IL-23 antagonists for treatment of infection